p-Tyr Inhibitors, also known as phospho-Tyrosine inhibitors, comprise a significant chemical class characterized by their ability to interact with and modulate proteins containing phosphorylated tyrosine residues. Phospho-tyrosine, a post-translational modification of the amino acid tyrosine, serves as a pivotal molecular switch in a wide range of cellular processes. These inhibitors play a crucial role in unraveling the intricate signaling networks that govern cell behavior by specifically binding to and interfering with phospho-tyrosine-mediated interactions.
Structurally, p-Tyr inhibitors exhibit distinct features that facilitate their engagement with phospho-tyrosine sites within target proteins. Often possessing well-defined three-dimensional architectures, these inhibitors are designed to complement the spatial arrangement of phospho-tyrosine-containing binding pockets. This allows for precise and effective interaction, disrupting the phospho-tyrosine-mediated functions of the protein. Additionally, p-Tyr inhibitors typically incorporate functional groups that form critical non-covalent interactions, such as hydrogen bonding and van der Waals forces, with the phospho-tyrosine residues. These interactions contribute to the high specificity and affinity of the inhibitors for their target sites. Research in the realm of p-Tyr inhibitors is a dynamic field that seeks to uncover the fundamental molecular mechanisms underpinning diverse cellular phenomena. By elucidating the interactions between these inhibitors and phospho-tyrosine-containing proteins, scientists gain insights into the intricate regulatory processes that dictate cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is an inhibitor of multiple tyrosine kinases | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets multiple tyrosine kinases, approved for CML and ALL. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Blocks EGFR tyrosine kinase, used in non-small cell lung cancer. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual HER2 and EGFR inhibitor, used for HER2+ breast cancer in research studies. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Targets multiple tyrosine kinases, used in idiopathic pulmonary fibrosis. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits multiple receptor tyrosine kinases, used in renal cell carcinoma. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Potent Bcr-Abl inhibitor, indicated for resistant CML and ALL. | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
ALK and ROS1 inhibitor, used in ALK-positive NSCLC. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Irreversible ErbB family blocker, used in NSCLC with EGFR mutations. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Targets multiple receptor kinases, used in renal cell carcinoma. | ||||||